Cartesian Therapeutics, Inc. — Director's Dealing 2024

Apr 11, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-04-08

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-08	Series A Non-Voting Convertible Preferred Stock	M	123925.407	—	Disposed	0	Direct
2024-04-08	Common Stock	M	4130846	—	Acquired	4379899	Direct
2024-04-08	Series A Non-Voting Convertible Preferred Stock	M	24785.081	—	Disposed	0	Indirect
2024-04-08	Common Stock	M	826169	—	Acquired	1927630	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3493	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$19.656	2034-01-01	Common Stock (7600)	7600	Direct
Warrant (Right to Buy)	$46.50	2027-04-11	Common Stock (167040)	167040	Indirect

Footnotes

F1: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock.

F2: On April 4, 2024, the issuer effected the "Reverse Stock Split". The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F3: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

F4: This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant.